Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – What’s Next?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped up prior to trading on Wednesday . The stock had previously closed at $10.85, but opened at $11.40. Telix Pharmaceuticals shares last traded at $11.56, with a volume of 86,235 shares traded.

Analyst Upgrades and Downgrades

Several brokerages have commented on TLX. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Finally, Wedbush restated an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.40.

Telix Pharmaceuticals Stock Performance

The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16. The company’s 50-day simple moving average is $11.16 and its 200-day simple moving average is $9.87.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Rhumbline Advisers raised its stake in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares during the period. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals during the 4th quarter worth approximately $89,000. Bank of America Corp DE increased its holdings in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the last quarter. OLD Mission Capital LLC acquired a new position in shares of Telix Pharmaceuticals during the 4th quarter worth approximately $111,000. Finally, XY Capital Ltd bought a new stake in Telix Pharmaceuticals in the 1st quarter valued at $120,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.